Life Sciences Opportunities in India & China: From Innovation to Commercialization
30 September 2009
China and India are emerging as major players in the life sciences industry. Both countries have a wealth of top talent as well as rapidly-improving resources for the industry. Both countries also constitute important current and potential markets for drugs, devices and diagnostics, and are also projected to be major sources of innovation in the not-too-distant future. This panel will explore the significant opportunities in China and India, in terms not only of expanding operations to both countries, but also in terms of working with innovative companies that originate from China and India.
Moderator:
- David A. Charapp, Special Counsel, Foley & Lardner LLP
Panelists:
- Stephen A. Bent, Partner, Foley & Lardner LLP
- Friedhelm Blobel, Ph.D., President, CEO, Director, SciClone Pharmaceuticals
- Kim Kamdar, Ph.D., Principal at Domain Associates
- Sanjay Shukla, M.D., M.S., Chief Executive Officer, RxMD
Related Insights
16 January 2025
Events
Silicon Slopes Summit 2025 Networking Reception
As Foley & Lardner continues to support Silicon Slopes Summit, our Innovative Technology sector has teamed up with Trustpoint.One, Silicon Valley Bank, Ampleo, and Tanner LLC to keep the conversation going after day four.
04 December 2024
Events
Data Privacy Minefields: Mastering FDA Compliance and Privacy Standards for Drug and Device Manufacturers
Foley partner Aaron Tantleff is speaking in the American Conference Institute’s 29th Annual Conference on Drug & Medical Device Litigation in a session titled “Data Privacy Minefields: Mastering FDA Compliance and Privacy Standards for Drug and Device Manufacturers.”
20 November 2024
PharmaPatents
USPTO Publishes Final Fees for 2025
The USPTO has published its final rule setting patent fees that will take effect January 19, 2025.